Section 4 of 6
Clinical evidence
188 evidence topics · 24 sources
Study summaries
AURORA
Objective
Primary objective: proportion of MG-ADL responders at Month 4
Study purpose and population: adults with AChR antibody-positive generalized myasthenia gravis
Location and study date
Registry study dates and recruitment status, September 2026 record
“Study Start (Actual) 2025-05-06” (opens the source at this quote in a new tab)
“Primary Completion (Estimated) 2026-12-30” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-09-30” (opens the source at this quote in a new tab)
“Last Update Posted 2026-09-01” (opens the source at this quote in a new tab)
Trial initiation: company statement
Registry site count and site locations by country
European Union member states, start of trial, and recruitment end dates
Estimated primary completion, March 2026 record, superseded in August 2026
Study design
Randomized, double-blind, placebo-controlled, multicenter phase 3 design
One-to-one randomization to six once-weekly outpatient infusions without preconditioning chemotherapy
Two study parts: double-blind Part 1 and open-label Part 2
Masked dosing and follow-up to Month 4, then optional Descartes-08 infusions: company trial schema
FDA Special Protocol Assessment agreement on the trial design, January 2025
Eligibility criteria
Age, disease classification, and MG-ADL threshold
Background immunosuppressive therapy and corticosteroid dose
Exclusions for disease duration, treatment history, and other neuromuscular disease
Washout periods for IVIg, plasma exchange, B-cell depleting agents, FcRn antagonists, and complement inhibitors
Infection, immunodeficiency, malignancy, and vaccination exclusions
Treatment
Descartes-08 arm: leukapheresis and manufactured autologous mRNA CAR T-cell therapy
Placebo arm: infusion without Descartes-08
Six weekly masked doses of Descartes-08 or placebo: company trial schema
Study outcomes
Rationale for using MG-ADL response as the primary endpoint
Primary endpoint: MG-ADL improvement of 3 points or more at Month 4 compared with placebo
Secondary endpoints: safety, MGC improvement of 4 points or more, QMG, and MG-QoL-15r
Secondary endpoints at Month 4 and over 1 year: company trial schema
MG-ADL instrument and its use as a primary endpoint in trials
“The Myasthenia Gravis Activities of Living (MG‐ADL) scale is an 8‐item patient‐reported scale that measures myasthenia gravis (MG) symptoms and functional status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of trials beginning in 2018 or later, 46.7% (n = 7) have used the MG‐ADL as a primary outcome compared to 10.0% (n = 2) of trials prior to 2018 (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sensitivity and specificity of 1-point and 3-point MG-ADL changes, and responder thresholds used in trials
“In this study, results from sensitivity and specificity analyses indicated that a 1‐point change in MG‐ADL was highly sensitive (96%) but did not have good specificity (71%), and a 3‐point change had good specificity (90%) but was not very sensitive (62%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these 13 studies, 53.8% (n = 7) used a 2‐point improvement only, 30.8% (n = 4) used a 3‐point improvement only, 7.6% (n = 1) showed results for improvements ranging from 2 to 8 points, and 7.6% (n = 1) did not report how an MG‐ADL responder was defined.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 2‐point responder threshold has been established in the mild to moderate MG population, but further research is needed to determine the appropriate responder threshold for a severe MG population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Precedent for a 3-point MG-ADL responder definition: REGAIN and the eculizumab label
“Results from the REGAIN trial showed that increasing the stringency of the responder definition at week 26 with higher thresholds revealed a more substantial difference between eculizumab and placebo (3‐point MG‐ADL improvement: 60% eculizumab responders, 40% placebo responders, P = .0229; 5‐point MG‐ADL improvement: 45% eculizumab responders, 25% placebo responders, P = .0182; 7‐point MG‐ADL improvement: 34% eculizumab responders, 10% placebo responders, P = .0007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, there is no publicly available regulatory guidance from the FDA on an appropriate MG‐ADL responder threshold, although the FDA label for eculizumab refers to REGAIN study results using a 3‐point improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Expert criticism of the MG-ADL as a phase 3 primary endpoint
“Although important to measure, the MG-Activities of Daily Living (MG-ADL) was thought not to assess the breadth of relevant daily activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As such, the MG-ADL score was considered “not appropriate” as a primary endpoint for phase 3 trials and was considered “a bar too low” for approval of a therapy, especially given the threshold of a 2-point improvement for clinically meaningful improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of approximately 100 participants: company statement, March 2026
Actual registry enrollment, September 2026 record
Estimated registry enrollment, March 2026 record, superseded in August 2026
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- AURORA has reported no efficacy or safety results. The registry record (last update posted 2026-09-01) lists the study as active and not recruiting, with estimated primary completion on 2026-12-30 and estimated study completion on 2027-09-30; record version 16 had listed estimated primary completion on 2026-11-30. The company expects a data readout in the first quarter of 2027.
- Enrollment differs by source: the company states approximately 100 participants, registry record version 16 listed an estimated enrollment of 100, and the current registry record lists an actual enrollment of 128.
- The primary endpoint is the proportion of participants with an MG-ADL improvement of 3 points or more at month 4 compared with placebo. The registry lists a crossover assignment model, a double-blind Part 1 of about 6 months, and an open-label Part 2 of about 8 months for eligible participants, and the company trial schema shows optional Descartes-08 infusions with follow-up at months 5, 6, 9, and 12.
- The phase 2b report stated plans to use the MGC score as the primary outcome in a subsequent phase 3 trial; in AURORA, MGC improvement of 4 points or more at month 4 is a secondary endpoint. One publication reports that the MG-ADL score was considered “a bar too low” for approval of a therapy given the 2-point threshold for clinically meaningful improvement. Another reports that a 3-point MG-ADL change had a specificity of 90% and a sensitivity of 62%, that no publicly available FDA guidance on an MG-ADL responder threshold exists, and that the eculizumab label refers to REGAIN results using a 3-point improvement.
- Eligibility is limited to adults with an anti-AChR antibody titer or anti-AChR cluster antibody above the reference upper normal limit, MGFA class 2 to 4, and an MG-ADL total score of 6 or more. Participants diagnosed within 12 months of screening, those with no history of systemic gMG treatment other than acetylcholinesterase inhibitors, those treated with rituximab or ocrelizumab within 12 months, and those with prior BCMA-directed therapy are excluded. In the phase 2b mITT population, 6 participants (23.1%) were triple seronegative and 1 (3.8%) was LRP4 autoantibody-positive.
- The company's Form 10-K states that a trial conducted under a Special Protocol Assessment agreement that meets its endpoints carries no guarantee that the FDA will accept or approve a marketing application.
Special Protocol Assessment agreement does not guarantee approval
MG-001 phase 2b
Objective
Objective: efficacy and safety of Descartes-08 versus placebo in generalized MG
Registered objective of the phase 2b study
Objective as stated in the September 2025 congress poster
Location and study date
Settings and countries
“MG-001 part 3 was a phase 2b, randomized, double-blind, placebo-controlled trial of Descartes-08 in patients with MGFA class II–IV gMG, conducted in academic medical centers and community neurology clinics in North America and Türkiye (ClinicalTrials.gov identifier: NCT04146051).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The trial was approved by regulatory authorities in each country (USA, Canada and Türkiye), the central and local institutional review boards in the USA (Western Institutional Review Board-Copernicus Group, WCG IRB, Puyallup, WA), and the ethics committee at each site in other countries (the research ethics boards at the University of Toronto and the University of Alberta, as well as the ethics committee at Istanbul University).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Screening period, November 2022 to January 2024
“A total of 50 participants were screened for eligibility in this study (MG-001 part 3) between November 10, 2022, and January 15, 2024 (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Part 3 was added to the MG-001 study protocol in amendment v3.0 (August 1, 2022).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Randomized, double-blind, placebo-controlled design with 12-month follow-up
“In this phase 2b, double-blind, placebo-controlled trial, eligible patients with gMG who tested negative for autoantibodies to MuSK were randomized 1:1 to receive six once-weekly intravenous infusions of Descartes-08 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study included a 12-month follow-up period to assess the efficacy of treatment using the MG Composite (MGC), MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Leukapheresis before randomization and placebo manufacture
“All eligible participants underwent leukapheresis and had a Descartes-08 lot and an acellular placebo lot manufactured under Good Manufacturing Practice conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following the successful manufacturing of the autologous product, participants enrolled in part 3 were randomized 1:1 to receive either Descartes-08 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Randomization and allocation concealment
“Randomization was performed centrally using a computer-generated permuted-block scheme without stratification (Mathematica v13.0, Wolfram Research).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Block sizes were varied and concealed from site personnel to maintain unpredictability in allocation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The random allocation sequence was generated by the study statistician and implemented centrally at the autologous lot manufacturing stage by sponsor staff who were otherwise uninvolved in the study conduct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding through the month 3 primary endpoint assessment
“Participants, study team members and all sponsor staff involved in the treatment or clinical evaluation of the patients, as well as in the review or analysis of data, were blinded to the treatment assignment until after the primary endpoint assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blinding of study personnel, clinic staff and participants during infusion was maintained using opaque coverings for the infusion bag and tubing, which were identical between Descartes-08 and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blinded follow-up occurred at 2 weeks (month 2) and 6 weeks (month 3) after the last infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Open-label crossover after month 3 and 12-month follow-up
“Both the study teams and participants were blinded to the treatment assignment through the month 3 visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After the primary endpoint assessment at month 3, participants randomized to placebo had the option to cross over to Descartes-08, which was administered under an open-label protocol.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants were followed up for 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rescue therapy
“Participants who demonstrated a ≥3-point worsening of the MG-ADL score from baseline or showed signs of an impending myasthenic crisis could receive rescue therapy, which, for those randomized to placebo, included Descartes-08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Independent study monitoring committee
Protocol amendments: enrollment cap, primary endpoint, and primary efficacy population
“Major amendments include v3.2 (October 17, 2023), which increased the enrollment cap to 50; v3.3 (January 8, 2024), which specified a 5-point reduction in the MGC score at month 3 as the primary endpoint; and v4.2 (June 19, 2024), which defined the primary efficacy population and outlined the use of the estimand framework for intercurrent events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria: age, MGFA class, background immunosuppression, and corticosteroid dose
“All participants were required to meet the following inclusion criteria: ≥18 years of age; a diagnosis of gMG, defined as MGFA clinical class III or IV (part 1; dose escalation) or class II–IV (parts 2–4) at the time of screening; use of concomitant immunosuppressive drugs deemed necessary by the investigator; daily dose of corticosteroids of ≤40 mg per day of prednisone equivalent, with a stable dose for a minimum of 4 weeks before the baseline visit” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“participants must have an MG-ADL total score of ≥6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inclusion criteria: seropositive and seronegative cohorts
“for the seropositive cohort only: MG-specific antibody titer must be above the reference laboratory’s upper limit of normal and documented within 10 years of screening (patients who were MuSK or LRP4 autoantibody-positive were allowed to be enrolled in parts 1 and 2 only and were not eligible for this trial)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“for the seronegative cohort only: unequivocal response to cholinesterase inhibitors and abnormal repetitive nerve stimulation or increased jitter (participants must not have another neuromuscular disease that may cause increased jitter and must have a negative congenital myasthenic syndrome panel)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who tested positive for MuSK autoantibodies were excluded from the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria: recent IVIg, plasma exchange, B-cell therapy, and biologics
“intravenous infusion of immunoglobulin or plasma exchange within 4 weeks before the baseline (day 1) visit; treatment with rituximab or ocrelizumab within 12 months before the baseline (first infusion) visit; treatment with calcineurin inhibitors (for example, tacrolimus, cyclosporine, cyclophosphamide), FcRn antagonists and/or other biologics within 3 weeks before the planned leukapheresis and within 8 weeks before the baseline (first infusion) visit; initiation of eculizumab treatment within 8 weeks before the baseline (first infusion) visit (patients who had been receiving eculizumab for more than 8 weeks and met other criteria for enrollment were eligible for treatment on the trial)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria: immunodeficiency, infection, malignancy, and live vaccines
“history of primary immunodeficiency or organ or allogeneic bone marrow transplant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“active tuberculosis or a positive QuantiFERON test at screening” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a history of malignancy that required treatment in the past 3 years, except for successfully treated squamous cell and/or basal cell carcinoma of the skin and/or breast or colon cancer that was surgically removed and did not require adjuvant chemotherapy or radiotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“receipt of a live vaccination within 4 weeks before baseline (day 1) or intent to receive live vaccination during the study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Six once-weekly infusions of Descartes-08 or placebo with 12-month follow-up
Protocol dose and comparison with background immunosuppression
Study outcomes
Rationale for using MGC response as the primary endpoint
Primary endpoint: 5-point or greater MGC decrease at month 3
“The primary endpoint was the proportion of participants who demonstrated a ≥5-point decrease in the MGC score at month 3 compared to baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MGC scale is a ten-item, 60-point weighted instrument composed of both patient-reported and provider-assessed items, which are themselves components of two other scales (MG-ADL and QMG).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MGC was recommended by the 2000 MGFA Task Force for MG trials” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 3-point change in the MGC score is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Change of the primary outcome from MG-ADL to MGC, January 2024
“On January 8, 2024, after the enrollment of 44 participants and before the unblinding of data and database lock, the steering committee of the trial, in consensus with the study monitoring committee, decided to implement a change in the primary outcome: from the MG-ADL score to the MGC score (previously a secondary outcome).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The original primary outcome (MG-ADL score) was changed to a secondary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This decision was made based on the recommendations of the 2000 MG Foundation of America (MGFA) Task Force” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with plans to use the MGC score as the primary outcome in a subsequent phase 3 trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consequently, the primary endpoint for this phase 2b study was a ≥5-point improvement in the MGC score at month 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the 5-point threshold: higher-than-expected baseline MGC scores
“Notably, the 5-point improvement cutoff is higher than the 3-point decrease in the MGC score considered to be clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This threshold was chosen to account for the higher-than-expected baseline MGC score compared to the scores observed in the MGC validation set” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the 5-point threshold: company statement, July 2024
Registered primary outcome measure
Secondary efficacy endpoints
“Secondary efficacy endpoints were the mean change from baseline in MGC, MG-ADL, QMG and MG-QoL-15r scores at each postinfusion visit (months 2, 3, 4, 6, 9 and 12), as well as the proportion of participants with ≥2–8-point improvements in MG-ADL, QMG and MGC scores at each postinfusion visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered secondary outcomes: 6-point responses and crossover participants
MG-ADL: instrument and clinically meaningful change
“The MG-ADL scale is an eight-item, 24-point, patient-reported instrument that assesses the effects of gMG on daily functioning” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 2-point change is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
QMG: instrument and clinically meaningful change
“The QMG scale is a standardized, 39-point scoring system consisting of 13 provider-assessed items, which include hand-grip strength and forced vital capacity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 3-point change is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety endpoints
“Safety endpoints included the occurrence of AEs and SAEs from the time of apheresis through month 12, as well as laboratory values and vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“AEs were coded using CTCAE version 5.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power calculation
“We estimated that 15 participants per treatment group would provide 80% power to detect a difference of 47% in responders between Descartes-08 and placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Calculations assumed 87% responders in the Descartes-08 group and 40% responders in the placebo group, based on a two-sample proportion test for independent samples to detect a difference in proportions at the 0.05 (nondirectional) level of significance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To account for screen failures and missed randomization due to insufficient cells manufactured, we enrolled up to 50 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed: safety population (36) and primary efficacy population (26)
“Thirty-six participants were deemed eligible and randomized to receive Descartes-08 (n = 20) or placebo (n = 16), comprising the safety population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-six participants were enrolled in an academic institution and had at least one postinfusion follow-up available, and they comprised the primary efficacy population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients (n = 26) were randomly allocated to receive once-weekly intravenous infusions of Descartes-08 (n = 15) or placebo (n = 11) over 6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed: company topline counts, July 2024, superseded in January 2026
Description of analysis sets
Primary efficacy (mITT) population restricted to academic-center participants
“Primary efficacy analyses were performed on a modified intention-to-treat (mITT) population, comprising all participants enrolled at an academic medical center who had at least one postbaseline follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline demographics and safety endpoints (that is, type and frequency of AEs) were analyzed in all enrolled participants using descriptive statistics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Protocol definitions of the mITT, ITT, and per-protocol populations
Primary endpoint analysis and handling of rescue and missing data
“The primary endpoint—the response status at month 3 (day 85), in which responders were defined as those who had a reduction of 5 points or more in their MGC total score compared to baseline—was analyzed using a two-independent-sample proportion test at a two-sided 5% significance level; a Wald chi-squared test was used to determine whether there was a significant association between the treatment group and the response status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who required rescue medication before day 85 had their MGC scores set to missing; these were imputed using baseline observation carried forward, with the response status set to nonresponder.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All other missing data were imputed using multiple imputation, assuming data were missing at random.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This was not required for the participants in the mITT population, as the data were complete.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup analyses
“Subgroup analyses were carried out to determine whether there was a difference in the response between participants who were anti-AChR antibody-positive and those who were anti-AChR antibody-negative, between those with early- and late-onset disease, between those with and without prior exposure to complement and FcRn inhibitors, and between those who did and did not develop a fever.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The difference in the proportion of responders was assessed, and the Wald chi-squared test for association between response status and subgroup was performed separately within each treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up efficacy dataset after month 3, company definition
Overall poster population combining per-protocol and mITT participants
Results
Participant disposition
Screening, leukapheresis, and manufacturing failures before randomization
“Of those, 45 participants met the inclusion criteria and underwent a single leukapheresis with a median of six doses produced (range, four to six doses).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In accordance with the protocol, 9 of the 45 participants (20.0%) were not randomized; they received Descartes-08 under an open-label protocol because they failed to meet the therapeutic dose requirements for treatment, as fewer than six doses were manufactured (results to be reported separately).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Withdrawal after two infusions
“One of the participants randomized to Descartes-08 withdrew from the study for reasons other than safety or efficacy after two infusions, and subsequent labs were not analyzed; therefore, 35 total randomized patients were analyzed in the correlative/mechanistic study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Placebo participants crossed over to Descartes-08 after month 3
Month 12 follow-up completion and loss to follow-up, March 2025 data cutoff
Baseline characteristics
Baseline demographics and disease characteristics, mITT population
Previous and ongoing MG therapies, mITT population
Disease severity and antibody status, mITT population
“Overall, 11 (73.3%) participants in the Descartes-08 group and 8 (72.7%) participants in the placebo group had MGFA class III or IV MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, two participants with MGFA class IIa MG were enrolled in the placebo group, whereas no participants with MGFA class IIa MG were enrolled in the Descartes-08 group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 19 (73.1%) were AChR autoantibody-positive, 1 (3.8%) was LRP4 autoantibody-positive and 6 (23.1%) were triple seronegative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Differences in concomitant therapy and prior biologic exposure between groups, mITT population
“The proportion of participants reporting concomitant use of nonsteroidal immunosuppressants was lower in the Descartes-08 group than in the placebo group (n = 6, 40.0% versus n = 8, 73.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median daily dose of concomitant prednisone equivalent was 20 mg (range, 5–25 mg) in the Descartes-08 group and 10 mg (range, 6–20 mg) in the placebo group, with no changes in dosing allowed before month 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Almost half of the participants in the Descartes-08 group (n = 7/15, 40.0%) and 6 of 11 (54.5%) participants in the placebo group received prior or ongoing complement inhibitors, and a third of participants in both groups received an FcRn inhibitor as prior treatment for their MG, indicating the refractory nature of the disease in a large proportion of study participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics of all randomized participants (safety population)
| Characteristic | Placebo (n=16) | Descartes-08 (n=20) |
|---|---|---|
| Female, % (n) | “62.5 (10)” | “55.0 (11)” |
| Age, years, mean (SD) | “57.8 (14.4)” | “59.4 (14.7)” |
| Median duration of disease, years (range) | “5 (1–23)” | “6 (0–26)” |
| MGFA class III at screening, % (n) | “68.8 (11)” | “70.0 (14)” |
| AChR+, % (n) | “75.0 (12)” | “80.0 (16)” |
| Sero-negative, % (n) | “25.0 (4)” | “15.0 (3)” |
| Diagnosis of thymoma, % (n) | “31.3 (5)” | “10.0 (2)” |
| Previous thymectomy, % (n) | “50.0 (8)” | “30.0 (6)” |
| Previous FcRn antagonist, % (n) | “37.5 (6)” | “30.0 (6)” |
| Previous complement inhibitor, % (n) | “37.5 (6)” | “15.0 (3)” |
Efficacy results
Primary endpoint and month 3 score changes, mITT population (Descartes-08 n = 15; placebo n = 11)
| MGC responder comparison at month 3 | Value |
|---|---|
| Difference in proportions (95% CI) | “0.39 (0.01–0.77)”View highlighted excerpt for this quote |
| P value | “0.0472”View highlighted excerpt for this quote |
Primary endpoint met at month 3, mITT population
“At month 3, the proportion of patients achieving a ≥5-point improvement in the MGC score was significantly higher for those treated with Descartes-08 compared to placebo in the overall population (66.7% (n = 10/15) versus 27.3% (n = 3/11), P = 0.0472) and in a subpopulation of those positive for autoantibodies to the acetylcholine receptor (63.6% (n = 7/11) versus 12.5% (n = 1/8), P = 0.0258).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statistical significance was determined using a two-sided two-independent-sample proportion test.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary endpoint, mITT population: company topline, July 2024, superseded in January 2026
Primary endpoint, per-protocol population: company topline, July 2024
MGC response and MG-ADL change at month 3, poster overall population (31 participants) and AChR+ population (24 participants), September 2025
| Population | Descartes-08 responders | Placebo responders | P value |
|---|---|---|---|
| “A. Overall population (n=31)” | “(n=12/18)”“67%” | “(n=4/13)”“31%” | “p value: 0.048” |
| “B. AChR+ population (n=24)” | “(n=9/14)”“64%” | “(n=2/10)”“20%” | “p value: 0.031” |
MG-ADL and QMG changes through month 12, Descartes-08 group, mITT population (open-label follow-up)
“Responses deepened further during the follow-up for those in the Descartes-08 group, with the mean (s.d.) MG-ADL score reduction reaching −5.5 (1.1) at month 4 (day 113), which was maintained at month 12 (mean (s.d.) score, −4.8 (1.4)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QMG score reductions also continued throughout the follow-up period in the Descartes-08 group, reaching maximum improvement at month 12 (mean (s.d.) score, −6.0 (2.1)).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients treated with Descartes-08, the changes from baseline in mean MGC, MG-ADL and QMG scores at month 4 were −7.1, −5.5 and −4.8, respectively, with 83.0% of patients achieving a sustained and clinically meaningful response at month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sustained clinically meaningful MG-ADL response at month 12, Descartes-08 group, mITT population
“In this phase 2b trial, the initial response rate was lower, with 10 of 15 participants (66.7%) achieving at least a 5-point improvement in the MGC score; however, all responses were maintained through 12 months, and 80.0% of participants had at least a clinically meaningful response 1 year after treatment, highlighting the durability of the effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sustained response at month 12: company update, December 2024, superseded in April 2025
Minimum symptom expression by month 6 and through month 12, Descartes-08 group, mITT population
“Minimum symptom expression (MSE), defined as an MG-ADL score of ≤1, was achieved by 33.3% (n = 4/12) of participants in the Descartes-08 group who reached month 6 of follow-up, and all individuals maintained this status through month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of those achieving MSE, two participants were AChR autoantibody-positive and two were triple seronegative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant in the placebo group who was triple seronegative achieved MSE status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, 33.0% of patients achieved minimum symptom expression (MSE) (MG-ADL score ≤1) by month 6, which was sustained through month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Corticosteroid dose reduction and absence of therapy escalation through month 12
“Tapering of the prednisone dose was allowed at the investigators’ discretion after the month 6 visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a median follow-up of 12 months, the median daily dose of orally administered prednisone equivalent in the Descartes-08 group was 9 mg (range, 2.5–20 mg), compared to 20 mg (range, 5–25 mg) at baseline—a 55.0% decrease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As there was no tapering allowed before month 6, the median dose in the placebo group remained unchanged throughout the follow-up at 10 mg (range, 6–20 mg).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the participants randomized to Descartes-08 required escalation in MG therapies for the duration of the study, including intravenous infusion of immunoglobulin or plasma exchange.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Placebo responses and secondary endpoint significance
“There were several notable placebo responses during the early follow-up in the overall cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although these responses were waning by the primary endpoint assessment at month 3, they led to a lack of statistical significance in the study’s secondary outcomes of efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-AChR antibody levels at month 3
“While there was no difference between the groups in AChR autoantibody levels at month 3, an exploratory assay of all autoreactive antibodies showed a significant difference in the change at month 3 between Descartes-08 and placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-AChR antibody levels at month 3: company presentation, October 2024, superseded in January 2026
Health-related quality of life and patient-reported outcomes
MG-QoL-15r, MG-ADL, and QMG change from baseline at month 3
“At month 3, the Descartes-08 group demonstrated substantially greater numerical and clinically meaningful reductions compared to the placebo group in the mean MG-ADL score (4.1 versus 1.6), QMG score (−3.9 versus −1.5) and MG-QoL-15r score (−5.7 versus −3.7) (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All clinical outcome measures showed greater improvement in the Descartes-08 group compared with the placebo group, including patient-reported outcomes as measured by the MG-ADL score, objective improvements in patient strength as measured by the QMG score and the combination of the two measured by the MGC score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MG-QoL-15r and other scales among Descartes-08 responders at month 3, July 2024
Safety results
Treatment-emergent adverse events, day 1 to month 3, safety population
“Treatment-emergent AEs from day 1 to month 3 for Descartes-08 and placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall adverse events and grade 3 events, safety population
“Adverse event (AE) rates were similar between groups, with 17 of 20 (85.0%) participants in the Descartes-08 group and 13 of 16 (81.3%) participants in the placebo group reporting at least one AE during the study (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most AEs were mild or moderate (Common Terminology Criteria for AEs (CTCAE) grades 1–2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 20 participants in the safety population randomized to Descartes-08 and 16 participants randomized to placebo, 5 (25.0%) and 2 (12.5%), respectively, experienced a grade 3 AE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Descartes-08 group, grade 3 AEs included a vasovagal reaction, a bacterial infection, fever, a herpes simplex virus (HSV) reactivation and a thromboembolic event (thrombosis of a central venous port placed several years before enrollment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meanwhile, grade 3 AEs reported in the placebo group included disease exacerbation and urinary tract infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, only the case of fever was deemed possibly treatment-related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events and absence of grade 4 or 5 events, safety population
“There were no grade 4 or 5 (death) events in either group for the duration of the study (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five serious AEs (SAEs) occurred in the Descartes-08 group (25.0%), while three SAEs occurred in the placebo group (18.8%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, three in the Descartes-08 group and one in the placebo group occurred after the first infusion: one each of an infusion-related reaction (IRR), syncope, HSV reactivation and hip fracture.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the three SAEs occurring after the first infusion in the Descartes-08 group, one (HSV reactivation) took place in an academic medical center, while two were reported in a community clinic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The only SAE deemed to be related to treatment was a grade 3 IRR manifesting as a fever of 40 °C, which started within 12 h of the fifth infusion and resolved within 48 h without the administration of tocilizumab or steroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infusion-related reactions: onset, management, and timing
“Generally, IRRs manifested as an acute onset of headache, nausea, fever, chills, arthralgia and myalgia within 8 h of infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In all but one case (the above-mentioned grade 3 IRR), IRRs were managed in an outpatient setting and resolved within 24 h without tocilizumab or steroid administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fevers, chills and myalgias typically occurred after doses two through five for participants who experienced these AEs, with four of six grade 2 fevers (39–40 °C) occurring after the second and third infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Postinfusion fever and cytokine release syndrome classification
“Due to the rapid onset and resolution of the severe fever without intervention, and in the absence of a concomitant increase in inflammatory markers commonly associated with cytokine release syndrome (CRS), this event was deemed to be an acute IRR.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our study, most participants randomized to Descartes-08 developed postinfusion fevers for approximately half of the administered infusions, which could be interpreted as grade 1 CRS” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, several properties of the observed fevers do not support this interpretation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infections and herpes simplex reactivation, safety population
“Infection rates were similar between the treatment groups, with more upper respiratory infections reported in the placebo group than in the Descartes-08 group (25.0% versus 15.0%), while more HSV reactivations were reported in the Descartes-08 group compared to the placebo group (15.0% versus 0%) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, all HSV reactivations occurred in patients with a prior history of labial herpes who were on concomitant azathioprine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
B cells, immunoglobulins, and vaccine titers
“There was no difference in total circulating B cell levels between the Descartes-08 and placebo groups, and there were no cases of hypogammaglobulinemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serum levels of vaccine titers were similar between the two groups at month 3 and were maintained through month 12 in the Descartes-08 group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events after month 3 through month 12
Treatment-emergent adverse events, AChR antibody-positive participants
| Event, n (%) | Descartes-08 (n=16) | Placebo (n=12) |
|---|---|---|
| Any AE | “16 (100)” | “12 (100)” |
| Serious AE | “4 (25.0)” | “2 (16.7)” |
| Any AE leading to discontinuation of study drug | “1 (6.3)” | “1 (8.3)” |
| Any infusion-related reaction | “13 (81.3)” | “7 (58.3)” |
| Fever | “8 (50.0)” | “1 (8.3)” |
| Chills | “10 (62.5)” | “0” |
| Any infection | “6 (37.5)” | “5 (41.7)” |
| Herpes simplex reactivation | “2 (12.5)” | “0” |
Study limitations
Summary
- Sample size and power: the authors describe a phase 2 study with a limited sample size and 80% power to detect differences in the primary outcome, which makes comparisons of secondary outcomes descriptive. The power calculation assumed 15 participants per group, 87% responders with Descartes-08, and 40% with placebo. Numerical differences in secondary scores did not meet the hierarchical threshold for formal testing, and placebo responses during early follow-up led to a lack of statistical significance in the secondary efficacy outcomes.
- Analysis sets: of 45 participants who underwent leukapheresis, 9 (20.0%) were not randomized because fewer than six doses were manufactured. Of 36 randomized participants (safety population), the primary efficacy analysis included the 26 enrolled at an academic medical center with at least one postinfusion follow-up. The protocol specified sensitivity analyses in the overall ITT and per-protocol populations. The company's 2024 topline release reported the mITT population as 14 Descartes-08 and 12 placebo participants and the safety population as 19 and 17, where the published report gives 15 and 11, and 20 and 16.
- Change of primary endpoint: on January 8, 2024, after 44 participants had enrolled and before unblinding and database lock, the primary outcome was changed from the MG-ADL score to the MGC score, and the 5-point MGC threshold, chosen to account for higher-than-expected baseline MGC scores, exceeds the 3-point change considered clinically meaningful. The primary efficacy population was defined in protocol amendment v4.2 (June 19, 2024).
- Allocation and baseline imbalance: randomization had no stratification by site, and the authors state that this, the small sample, and the rate of participants not randomized likely led to unequal allocation. Disease duration and the rate of thymoma were higher in the placebo group, and triple seronegative participants (23.1%) were overrepresented compared with the general population, which the authors state affected the magnitude of the early placebo response. A transient effect of leukapheresis cannot be excluded.
- Subgroups: subgroup analyses compared participants by AChR antibody status, early- or late-onset disease (a prespecified analysis), prior exposure to complement and FcRn inhibitors, and development of fever, and an analysis of cell dose and MGC response was post hoc. The authors state that the small sample and heterogeneous population severely limit inferences about subgroups, and that the difference between biologic-naive and biologic-exposed participants may represent a true difference in biology, an artifact of a small sample size, or more treatment-refractory disease.
- Follow-up beyond month 3: all 11 placebo participants received open-label Descartes-08 after month 3, and month 4 to month 12 results are reported for the Descartes-08 group. As of a March 31, 2025 cutoff, the company reported that 12 of 15 Descartes-08 participants in the primary efficacy dataset completed month 12 and that 3 were lost to follow-up after month 3, 2 of whom were MGC responders at month 3.
- Other author-stated limitations: radioimmunoassay antibody testing may be insufficiently sensitive to changes in antibody subtype, mode of activity, and epitope; the protocol held prednisone stable until month 6 and allowed no change in nonsteroidal immunosuppressants; and fevers, chills, and myalgias were more common with Descartes-08 and may have affected the assessment of severity scales.
- Figures that differ between sources or within the report: sustained clinically meaningful response at month 12 is 83.0% in the abstract and 80.0% in the Discussion; minimum symptom expression is 33.0% in the abstract and 33.3% (4/12) in the Results; minimum symptom expression among biologic-naive participants is 55.60% in the abstract and 55.6% (5/9) in the Results, and the company's April 2025 release gives 57% (4/7) for biologic-naive participants with follow-up beyond month 3. The value −4.8 is reported both for the month-12 MG-ADL change and for the month-4 QMG change. The placebo MG-ADL change at month 3 in the AChR antibody-positive subgroup is 0.6 in the paper and −0.6 in a 2026 company slide presentation. The text reports prior or ongoing complement inhibitor use in the Descartes-08 group as “n = 7/15, 40.0%”.
Sample size, power, and descriptive secondary comparisons
“First, although randomized and placebo-controlled, this was a phase 2 study with a limited sample size and modest power (80%) to detect differences in the primary outcome, making any comparisons in secondary outcomes purely descriptive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Numerical differences between treatment group scores did not meet the hierarchical threshold for formal testing and were, therefore, not analyzed for statistical significance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In combination with the heterogeneous population enrolled, in terms of both gMG antibody type and prior treatment history, the small sample size also severely limits any inferences that can be made about the subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Allocation and baseline imbalance
“The lack of stratification by site, combined with the small sample size and a higher-than-anticipated rate of enrolled participants not being randomized, likely led to unequal allocation between the active group and the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, due to the small sample size, there was an imbalance in several disease characteristics, such as disease duration and the rate of thymoma, both of which were higher in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overrepresentation of triple seronegative participants and possible leukapheresis effect
“Third, although a minority of participants (23.1%) were triple seronegative, this was still an overrepresentation compared to the general population, significantly affecting the magnitude of the early response observed in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, a transient effect of leukapheresis cannot be excluded, particularly as therapeutic plasma exchange is a common treatment option for refractory MG” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antibody assay sensitivity
“Fourth, disease-specific antibodies were surveyed using radioimmunoassay in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, which, although in line with standard clinical practice, may be insufficiently sensitive to the changes in antibody subtype, mode of activity and epitope being targeted” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fixed background immunosuppression
“Fifth, the protocol mandated keeping the dose of prednisone stable until the month 6 visit (limiting the time available for dose de-escalation to 6 months) and did not allow any changes in the dose of nonsteroidal immunosuppressants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Possible unblinding through infusion-related reactions
MG-001 phase 1b/2a
Objective
Primary objective of safety and tolerability; secondary objectives of disease severity and biomarkers
Protocol objectives: safety, tolerability, and manufacturing feasibility
Objectives of the phase 1b and phase 2a portions: maximum tolerated dose and dosing schedule
Objective of the 12-month follow-up and retreatment report
“We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here, we report the results of both the final, 12‐month follow‐up analyses and the optional retreatment of participants who met protocol‐specific retreatment criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Eight U.S. sites, recruitment January 2020 to August 2022
Academic centers and community neurology clinics
Study design
Prospective, open-label, multicenter, nonrandomized phase 1b/2a design
Part 1 intrapatient dose escalation and Part 2 dosing schedules
“Part-2 (n=11) tested 3 dosing schedules at the MTD: twice weekly for 3 weeks (Arm-1), weekly for 6 weeks (Arm-2), and monthly for 6 months (Arm-3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enrollment into Part-2 would stop when sufficient data on safety, feasibility, and clinical activity had been gathered to permit the selection of the dosing schedule to be tested in later-stage trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Assignment to Part 2 arms by investigator discretion and participant preference
“Participants in Part-2 were assigned to a treatment Arm at investigator’s discretion, taking into consideration each participant’s preferences (predominantly determined by the time burden of each infusion schedule) and enrolment to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Assessment schedule and safety monitoring committee
“Participants were evaluated at screening, infusion visits, Weeks 8, 12, 16, and 20, and Months 6, 9, and 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Throughout the study, the clinical data were reviewed periodically by a sponsor-funded safety monitoring committee containing experts who have no other relationship with the sponsor or trial conduct.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term follow-up schedule of the weekly-dosing arm
“The group that received Descartes‐08 as six weekly infusions (Arm‐2) had the longest follow‐up, with evaluations at Months 2, 3, 4, 5, 6, 9, and 12 counting from the first infusion, and was therefore included in this analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Key inclusion criteria: age, MGFA class, autoantibody status, and MG-ADL score
“Key inclusion criteria were: age ≥18 years; diagnosis of MG (MGFA Disease Class III–IV in Part-1, Class II–IV in Part-2) with presence of an MG-associated autoantibody (anti-acetylcholine receptor [AChR], muscle specific kinase [MuSK], or low-density lipoprotein receptor-related protein 4 [LRP4]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If seronegative, unequivocal response to cholinesterase inhibitors, and abnormal repetitive nerve stimulation, or increased jitter on single-fiber EMG was required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had to have MG Activities of Daily Living (MG-ADL) score ≥6 at both screening and baseline; and requiring immunosuppression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria
“Key exclusion criteria were the presence of a major chronic illness that was not well managed; IVIg or plasma exchange within 4 weeks of baseline (first infusion) visit; and the use of non-permitted immune modulators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stable background immunosuppression required before enrollment
Protocol exclusions for B-cell depleting agents, calcineurin inhibitors, FcRn antagonists, and complement inhibitors
Protocol exclusions for hepatitis, HIV, tuberculosis, and active infection
Treatment
Autologous CD8+ T-cell product transfected with RNA, prepared from leukapheresis without withholding immunosuppression
“Descartes-08 is an autologous CD8+ T-cell-only product that is transfected with RNA to express anti-BCMA targeting CAR protein over the course of a week.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible participants underwent leukapheresis to obtain peripheral blood mononuclear cells (PBMCs), from which Descartes-08 was prepared following Good Manufacturing Practices.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Immunosuppression was not withheld before the collection of PBMCs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Aliquot(s) of cells were thawed at each infusion visit and infused by a peripheral intravenous line.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 1 dose levels and Part 2 dose of 52.5 × 10⁶ CAR+ cells per kilogram
“In Part-1 of the study (n=3), each participant received three ascending weekly doses of Descartes-08 as a 15–30-minute intravenous infusion of 3·5 × 10⁶ CAR+ cells/kg (Dose Level 1, DL1) 17·5 × 10⁶ CAR+ cells/kg (DL2), and 52·5 × 10⁶ CAR+ cells/kg (DL3) to determine the maximum tolerated dose (MTD) at the safety interim analysis, prior to proceeding to Part-2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The allowed dose margin was ±45% for all dose levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part‐2, up to 10 participants per arm with MGFA Class II–IV AChR‐Ab+, MuSK‐Ab+, or seronegative MG received the maximum administered dose of Descartes‐08 from Part‐1—which was 52.5 × 10⁶ viable CAR+ cells per kilogram—twice‐weekly for 3 weeks (Arm‐1), once‐weekly for 6 weeks (Arm‐2) or once‐monthly for 6 months (Arm‐3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care setting, post-infusion monitoring, premedication, and no lymphodepletion
“Lymphodepletion chemotherapy was not used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For Part-1, participants were admitted to the hospital for their first infusion and observed as inpatient for three days and thereafter as outpatient daily until Day 7.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who received Descartes-08 as outpatients were observed for an hour post-infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Any participant with a fever of ≥38°C (≥100·4°F) within 7 days of infusion was admitted for 24-hour observation and evaluated for an infectious etiology with blood and urine cultures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Descartes‐08 was administered in an outpatient setting with 2 h of post‐infusion monitoring and without lymphodepletion chemotherapy (Figure 1A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both parts, the participants received acetaminophen and diphenhydramine as premedication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Permitted and prohibited concomitant medications
“Permitted MG concomitant medications were corticosteroids (≤40 mg prednisone/day equivalent), azathioprine, mycophenolate mofetil, pyridostigmine and complement inhibitors, provided the dose was stable for at least 8 weeks before the first infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dosing change was allowed for concomitant MG-specific medications during the study, other than corticosteroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The dose of corticosteroids was not allowed to be increased but it could be tapered at the site investigator’s discretion after Week 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intravenous immunoglobulin (IVIg) and plasma exchange (PLEX) were prohibited within 4 weeks of baseline and during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other biologics, including rituximab and efgartigimod, were prohibited within 8 weeks of baseline and during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturing from all participants and cell doses delivered
“We successfully produced Descartes-08 from all patients despite their use of immunosuppressants, with a potency comparable to a healthy volunteer (Figure s1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three Part-1 participants received a median of 6·4 × 10⁹ CAR+ cells (range 6·3–7·2) over three infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part-2, 11 participants received a median of 17·3 × 10⁹ CAR+ cells (range 9·65–33·12) divided across a median of six infusions (range 3–6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Primary endpoints: tolerability in Part 1 and adverse events in Part 2
“The primary objective of Part-1 was to determine tolerability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint of Part-2 was safety (frequency and severity of AEs) to final follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale: toxicities of DNA CAR T-cells and the premise of RNA engineering
“These aspects of DNA CAR T-cells limit their suitability for use beyond advanced cancers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To expand the range of conditions treatable with CAR T-cells beyond cancer, we engineered these cells with RNA (rCAR-T), rather than DNA, on the premise that the temporary, non-replicable influence of mRNA would confer predictable PK and consequently a more favorable safety profile.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary endpoints: MG-ADL, QMG, MGC, MG-QoL-15r, and MG PIS without a prespecified efficacy time point
“Secondary endpoints were mean changes from baseline at each follow-up visit for up to 12 months (a primary efficacy time point was not pre-specified) in four validated scales of MG severity: Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative MG (QMG), MG Composite (MGC), and MG Quality of Life 15-revised (MG-QoL-15r) scores, as well as the MG Post-Intervention Status (MG PIS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Protocol responder endpoints: 2-point MG-ADL and QMG changes and 3-point MGC change
Outcome scales and clinically meaningful change thresholds
“MG-ADL is an 8-item, 24-point, patient-reported scale that assesses the impact of myasthenic symptoms on daily functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By convention, a 2-point change is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QMG is a standardized, quantitative, 39-point scoring system consisting of 13 provider-assessed items, which include hand grip strength and forced vital capacity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MGC is a 10-item, 60-point weighted instrument composed of selected components of the MG-ADL and QMG scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A 3-point change in QMG and MGC is considered clinically meaningful.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Currently, there is no consensus as to what is considered a clinically meaningful change in MG-QoL-15r.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment: up to 18 participants
Enrolled participants: 3 in Part 1 and 11 in Part 2
Weekly-dosing arm analyzed through 12 months: 7 participants
Description of analysis sets
Safety analysis set: all 14 participants who received at least one dose
Week 12 efficacy set: Part 2 Arm 1 and Arm 2 participants who completed 12-week follow-up
“Includes data from Part-2 (Arm-1 and Arm-2) participants who completed 12-week follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One Arm 1 participant was off-study prior to the first post-treatment assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive statistical methods
“Baseline demographics and primary endpoints (type and frequency of AEs) were analyzed using descriptive statistics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary and exploratory endpoints were expressed as mean change with a 95% Confidence Interval (CI), or proportion with Standard Error (SE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Screening, eligibility failures, and withdrawals
“Sixteen patients were screened. Two did not qualify due to low baseline MG-ADL score (n=1) or lack of generalized disease (n=1) (Figure 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two of the 11 participants (18%) in Part-2 withdrew and did not complete all planned infusions: one due to urticaria (Arm 1, see below) and another for personal reasons unrelated to safety (Arm 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The single Arm-3 participant withdrew from study after receiving 3 of 6 planned monthly infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up duration and Arm 1 discontinuations by Week 16
“Median follow-up in Part-2 was 5 months (range: 3–9 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By Week 16, all Arm-1 participants were off-study due to AE (n=1) or worsening symptoms requiring additional treatment (n=2); all 7 Arm-2 participants continue having MG scale scores below baseline during 6 months median follow-up (range 4–9 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Arm 1 and Arm 3 discontinuation before full follow-up
Baseline characteristics
Demographics and baseline characteristics by part and arm: all 14 participants
Disease severity at screening, antibody status, and concomitant therapy: all 14 participants
“Most participants (10 of 14, 71%) had MGFA class III disease, with a median MG-ADL score of 11 (range 6–15), median QMG score of 16 (range 8–24), and median MGC score of 23 (range 12–30) at screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven patients had a history of anti-AChR antibodies; two had anti-MuSK antibodies; and one was seronegative for AChR, MuSK and LRP4 antibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most participants (11 of 14, 79%) continued pyridostigmine, and 10 of 14 (71%) received corticosteroids throughout the study (mean dose 19.5 mg/day, range 5–40 mg/day).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants had previously received at least one of the following: IVIg, corticosteroids, non-steroidal immune suppressants, or PLEX (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm characteristics: 7 participants
“Seven patients were enrolled in Arm‐2, of whom 5 were females, 4 (57%) were AChR‐Ab+, 3 (43%) had previously undergone thymectomy, and all had received previous immunosuppressive treatments and IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most participants continued the use of pyridostigmine and corticosteroids throughout the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Part 1: variable reductions in severity scores and one prednisone taper
“Part-1 participants showed variable reductions in mean MG-ADL, QMG, MGC, and QoL-15r scores at Weeks 3–24 (Figure s2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant tapered their dose of prednisone from 40 mg daily before treatment to 25 mg daily at final (12-month) follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 2 Arms 1 and 2: mean changes at Week 12 and onset of response
“Part-2 participants enrolled in Arms 1 and 2 experienced decreases in all disease severity scores by Week 5; in Arm-2, these reductions deepened further by Week 8 and subsequently plateaued (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean [95% CI] improvements at Week 12 — the last time point when data for all Arm-1 and Arm-2 participants were available — were −5·9 [−9, −2·8] (MG-ADL), −7 [−11, −3] (QMG), −14 [−19, −9] (MGC), and −9 [−15, −3] (MG-QoL-15r) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Repeatable numerical improvement in multiple MG scales pointing towards clinical symptom improvement was observed in all 9 participants who reached Week 8, and 8 of 9 (89%) at Week 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Measures of disease severity at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up
Responder definitions: prespecified 2-point and reported 3-point QMG thresholds, and post hoc MG-ADL depth of response
“All participants who had the pre-specified ≥2-point improvement in QMG also had a ≥3-point improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post-hoc analysis of depth of response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal symptom expression, IVIg independence, and concomitant medications: Part 2 Arm 2
“Three Arm-2 participants (43%) achieved minimal symptom expression (MSE, defined as MG-ADL of 0 or 1)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“in at least one post-treatment follow-up; two of the three have maintained MSE through the most recent (6-month) follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two other Arm-2 participants who, before enrollment, required weekly or biweekly IVIg infusions have not needed further IVIg during follow-ups at 4 and 6 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no changes in concomitant MG-specific medications reported in any Part-2 participants during the study period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm at Month 3: clinically meaningful improvement in all 7 participants
“All seven participants who received six weekly infusions of Descartes‐08 exhibited clinically meaningful improvement in common MG severity scales (MG Composite, MG Activities of Daily Living, Quantitative MG scores, and Quality of Life 15‐revised) at Month 3 without significant toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm at Month 9: mean changes in MG-ADL, MGC, QMG, and QoL-15r, 7 participants
“At Month 9, approximately 7 months after the last infusion and without new or increased MG‐directed drugs, all participants continued to experience substantial clinical responses as measured by MG‐ADL (mean change −6.3 [95% CI −3.5 to −9.1], Figure 2A), MGC (−16.6 [−13.4 to −19.5], Figure 2B), QMG (−8.4 [−5.2 to −11.6], Figure 2C), and QoL‐15r (−12 [−8 to −16], Figure 2D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm at Month 12: maintained response in 5 of 7 participants
“At Month 12, 5 of the 7 participants maintained clinically meaningful improvement, including one with MSE, with mean change in MG‐ADL −4.6 [95% CI −8.8 to −0.4], MGC −11.3 [−18.0 to −4.6], QMG −6.3 [−10.5 to −2.0] and QoL‐15r −7.7 [−15.6 to −8.4].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this 12‐month follow‐up, we observed durable responses sustained up to 12 months in 5 of the 7 (71%) participants who received six once‐weekly doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm: prednisone dose and IVIg use through Month 12
“Five of the 7 participants received prednisone at baseline, with a median daily dose of 17.5 mg. By Month 12, the median dose decreased to 5 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neither of the two participants who were receiving IVIG once and twice monthly at baseline required IVIG during the 12 months of follow‐up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm: anti-AChR antibody reductions through Month 12
“Three of the four participants with reported anti‐AChR antibody exhibited detectable levels at baseline, and all three showed reductions in antibody levels by Month 6 (−17%, −44%, and −65%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These reductions continued at Month 9 (−35%, −100% [undetectable], and −70%), and persisted at Month 12 (−33%, −44% and −65% reductions, Figure 5A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Relapse at Month 12 and Month 18 and retreatment in the weekly-dosing arm
“Two participants with anti‐AChR antibody‐positive MG experienced worsening disease at Month 12 and became eligible for retreatment (Table S1); both opted for retreatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Month 18 after initial treatment, a third participant, with triple‐seronegative MG, experienced MG worsening and opted for retreatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retreatment consisted of repeat apheresis followed by six once‐weekly infusions of target 52.5 × 10⁶ viable CAR+ cells per kg in an outpatient setting and without lymphodepletion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All three participants experienced a rapid improvement in MG‐specific clinical scores; two achieved MSE by Week 8, which was maintained through 12 months of post retreatment follow‐up (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The third participant experienced similar improvement in MG severity scores to their initial treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company-reported retreatment analysis: third phase 2a retreated participant at Month 12
Company-reported retreatment analysis: pooled phase 2a and 2b case series design, September 2026
Company-reported retreatment analysis: baseline characteristics of the pooled case series, 5 participants
| Characteristic | Participants (n=5) |
|---|---|
| Age, mean (SD) | “58 (12) years” |
| Age range | “49–79” |
| Women, n (%) | “4 (80%)” |
| AChR+ gMG, n (%) | “4 (80%)” |
| MG-ADL at baseline before initial treatment, mean (SD) | “9.2 (3.1)” |
| MG-ADL at baseline before retreatment, mean (SD) | “9.6 (3.4)” |
| Median interval between end of initial treatment course and first retreatment infusion | “16.6 months”; “(range 11.7–22.6)” |
Company-reported retreatment analysis: MG-ADL and MGC changes at Month 12 after retreatment, 5 participants
Health-related quality of life and patient-reported outcomes
MG-QoL-15r change at Week 12 by arm and antibody type: Part 2 participants with 12-week follow-up
| Measure at Week 12 | All, n=9 (mean change, 95% CI) | Arm 1, n=2 (individual values) | Arm 2, n=7 (mean change, 95% CI) | AChR+, n=6 (mean change, 95% CI) | MuSK+, n=2 (individual values) | Seronegative, n=1 |
|---|---|---|---|---|---|---|
| MG-QoL-15r | “−9 [−15, −3]”View highlighted excerpt for this quote | “−8, +4”View highlighted excerpt for this quote | “−11 [−23, +1]”View highlighted excerpt for this quote | “−8 [−17, +1]”View highlighted excerpt for this quote | “−10, −6”View highlighted excerpt for this quote | “−14”View highlighted excerpt for this quote |
Safety results
No dose-limiting toxicity, cytokine release syndrome, or neurotoxicity
“There was no dose-limiting toxicity, cytokine release syndrome (CRS), or neurotoxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no dose-limiting toxicities (DLTs), treatment-related SAEs, or Grade ≥3 AEs in Part-1 (Table 2), making DL3 the MTD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events: influenza before treatment, grade 3 urticaria, and myocardial infarction
“One SAE unrelated to Descartes-08 (Grade 2 influenza requiring hospitalization, which occurred after apheresis but before treatment initiation) was reported in Part-1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two SAEs were reported in Part-2. The first was Grade 3 urticaria 24 hours after the third infusion in a participant with a prior history of drug-induced urticaria; skin biopsy was consistent with a typical drug reaction, and serum tryptase and cytokine levels were normal (Table s3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The urticaria was deemed possibly related to Descartes-08 and resolved completely after the administration of intravenous steroids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The second SAE was a non-ST segment elevation myocardial infarction occurring 72 hours after the sixth infusion in an 83-year-old man with a history of hypertension and hyperlipidemia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The investigator deemed the event unrelated to Descartes-08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events related to Descartes-08 by part and arm: all 14 participants
Adverse event counting rules and grade distribution
“Each AE was counted once per patient, at the highest grade reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Relatedness includes possibly, probably, or likely” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no Grade ≥3 events reported in Part-1, and no Grade 2 or Grade 4 events reported in Part-2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Infusion-associated fever without cytokine release syndrome markers
“Headache, fever, and nausea were the most common treatment-related AEs in Part-2, reported in 5 (45%), 4 (36%), and 4 (36%) of 14 patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All fevers occurred 4–6 hours after infusion and resolved within 24 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of these patients had positive urine or blood cultures or received empiric antibiotics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no episodes of hypotension, hypoxia, or requirement for the use of tocilizumab or steroids for treatment of or prevention of CRS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fevers were not associated with elevated markers of CRS (interleukin-6, interleukin-2, and tumor necrosis factor-α).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Humoral immunity: immunoglobulins and vaccine titers through Week 12
“No patient showed evidence of functional immunosuppression (i.e. new hypogammaglobulinemia or disappearance of previously therapeutic levels of vaccine titers) or opportunistic infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anti-tetanus IgG antibodies were detected in all 9 participants (median [range] at Day 1 93·7 [8·5–850·9] Units/mL) and did not change (Figure 3G).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median total IgG among the 9 participants was 1325 [range 383–2862] mg/dL and decreased up to 18% [95%CI −6–42%] by Week 12, while IgA and IgM levels remained unchanged during treatment (Figures 3H–I).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly-dosing arm through Month 12: no new product-related adverse events
Weekly-dosing arm through Month 12: meningococcal antibody titers and total immunoglobulin
“Five of the seven participants had circulating anti‐meningococcal antibodies at baseline, all from prior vaccination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was a small but detectable decrease in these antibodies at Month 3, which deepened by Month 9 (−48% [−25% to −75%]) and stabilized by Month 12 to lower but still protective levels (−48% [−35% to −69%], Figure 5B), following a similar pattern to the anti‐AChR antibody reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, there was no appreciable decrease in total immunoglobulin (Figure 5C), other vaccine‐associated antibodies (Figure S1), or soluble BCMA (sBCMA, Figure 6A), indicating that the targeting of BCMA‐positive plasma cells was not indiscriminate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cumulative open-label safety: anaphylaxis, CRS, ICANS, and hematologic toxicity across 14 participants and 88 infusions
“In contrast, there were no cases of anaphylaxis reported across 14 patients treated and 88 administered infusions with Descartes‐08 in MG, including in 3 participants who received a total of 12 infusions each.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No cases of CRS or ICANS were observed among the 14 open‐label MG‐001 participants dosed with Descartes‐08, and no reported use of tocilizumab or corticosteroid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As there is no lymphodepletion chemotherapy required, there were no associated hematologic toxicities in any of the 14 patients with MG who received Descartes‐08.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety after retreatment in the weekly-dosing arm, 3 participants
“The safety profile was unchanged compared to the initial treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, the three participants reported fewer adverse events after retreatment while experiencing the same or better numeric improvement across MG severity scales all the way to MSE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company-reported retreatment analysis: safety events after initial treatment and retreatment, 5 participants
| Safety event | Initial treatment (n=5) | Retreatment (n=5) |
|---|---|---|
| Serious adverse events | “1” | “0” |
| Infusion-related reaction | “16/30 infusions” | “17/30 infusions” |
| Infusion-related reaction, grade 1 | “10” | “12” |
| Infusion-related reaction, grade 2 | “6” | “5” |
| Tachycardia | “1” | “5” |
| CRS | “0” | “0” |
| ICANS | “0” | “0” |
| Cytopenias | “0” | “0” |
| Hypogammaglobulinemia | “0” | “0” |
Company-reported retreatment analysis: tolerability through Month 12 after retreatment
Study limitations
Summary
- Design: the study was open label, nonrandomized, and without a control arm, and the authors state that a placebo effect cannot be excluded and that comparison with historical controls is not conclusive. Part 2 participants were assigned to dosing arms at the investigator's discretion, taking participant preference into account.
- Sample size: 14 participants were enrolled (3 in Part 1 and 11 in Part 2), and no formal power analysis was performed. The week 12 efficacy analysis included 9 Part 2 participants, and only 2 participants had MuSK antibody-positive disease and 1 had seronegative disease. Three participants had MGFA class II disease, which the authors note may improve to minimum symptom expression with conventional treatment.
- Endpoints: efficacy measures were secondary endpoints with no prespecified primary efficacy time point, and the analysis of MG-ADL decreases of 6 points or more was post hoc. Corticosteroid tapering was permitted after week 4 at the investigator's discretion, and the authors state that an effect of the unchanged maintenance dose cannot be excluded in the absence of a control arm.
- Follow-up and attrition: median follow-up in Part 2 was 5 months (range 3 to 9) in the initial report. By week 16 all twice-weekly arm participants were off study (adverse event, n = 1; worsening symptoms, n = 2), and the single monthly-arm participant withdrew after 3 of 6 infusions. The 12-month analysis is limited to the 7 weekly-arm participants, of whom 5 maintained clinically meaningful improvement at month 12.
- Retreatment and biomarkers: the authors state that more experience with initial treatment and retreatment is needed, that allergic reactions including anaphylaxis cannot be excluded, and that circulating antibody titers may not reflect tissue concentrations. The pooled retreatment case series of 5 participants is company-reported.
- Reporting: the sponsor took part in the design, data collection, interpretation, analysis, manuscript writing, and decision to submit. The text gives the most common treatment-related adverse events in Part 2 as 5 (45%), 4 (36%), and 4 (36%) “of 14 patients”, while the table reports these counts for Part 2 (n = 11). The month-12 MG-QoL-15r change is printed as “−7.7 [−15.6 to −8.4]”, an interval that does not contain its point estimate.
Small, open-label, uncontrolled design: author-stated limitations
“Our study has the inherent limitations of a small, open-label trial, including the potential for placebo effect, and limited ability to draw inferences from secondary, exploratory and subgroup analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, three participants had MGFA Class II MG, which may improve to MSE even with conventional treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although it is unlikely that the observed magnitude of symptom improvement could be attributed solely to this unchanged maintenance dose, or to the placebo effect, in the absence of a control arm such a possibility cannot be excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Third, there were only 2 participants with MuSK, and only 1 with seronegative MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Comparison to historical controls is not conclusive, and therefore a more complete assessment of efficacy is underway in a randomized, placebo-controlled study using six weekly doses of Descartes-08 for MG (NCT04146051).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor role in design, analysis, and reporting
Limited retreatment experience, allergic reactions, and antibody titers as biomarkers
“More experience with initial treatment and retreatment would be needed to confirm this hypothesis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As with any form of biologic therapy, allergic reactions, including anaphylaxis, cannot be excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the onset of clinical improvement was more rapid than the autoantibody reduction, and circulating antibody titers may not accurately reflect their concentration at the tissue level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote